Genmab A/S

GMAB

Equity

ISIN DK0010272202 / Valor 1129757

Nasdaq Copenhagen Equities (2026-03-26)

DKK 1,693.50+1.26%

Genmab A/S
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Genmab A/S is a biotechnology company specializing in the development of innovative antibody therapeutics for the treatment of cancer and other serious diseases. Founded in 1999 and headquartered in Copenhagen, Denmark, Genmab focuses on creating differentiated antibody products with the potential to improve patient outcomes. The company has developed several notable therapies, including DARZALEX, a monoclonal antibody for multiple myeloma, which is commercialized by Janssen, and TEPEZZA, used for thyroid eye disease, commercialized by Amgen. Genmab is also involved in the development of epcoritamab, a bispecific antibody for B-cell malignancies, with regulatory applications submitted in the US and Japan, and its partner AbbVie handling filings in the EU. Through strategic partnerships and a robust pipeline, Genmab aims to advance its position in the biopharmaceutical industry by delivering transformative medicines.

Summarized from source with an LLMView SourceSector: Technology

Latest Results ():

Summarized from source with an LLMView Source

Key figures

24.9%1Y

-34.3%3Y

-17.2%5Y

Performance

35.1%1Y

32.7%3Y

31.9%5Y

Volatility